Xifaxan 550 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26F3FZ8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,097
Award facts
- Contract value 100% obligated
- $38,096.53 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $38,096.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 28, 2026, for the supply of Xifaxan 550 mg tablets (60-count units). The contract, which carries no set-aside designation and is fully competitively awarded, is scheduled for ultimate completion on January 29, 2026, with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp functions as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, from specialty medications and brand-name drugs to vaccines and medical devices. This award for Xifaxan, an antibiotic medication commonly used for gastrointestinal conditions, exemplifies the routine delivery order activity conducted under the larger prime vendor contract framework that enables efficient fulfillment of government pharmaceutical and medical supply needs.
Quick answers
Who was awarded contract SPE2DR26F3FZ8?
SPE2DR26F3FZ8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26F3FZ8 worth?
The government has obligated $38,097 on SPE2DR26F3FZ8.
Is contract SPE2DR26F3FZ8 an order under another contract?
Yes. SPE2DR26F3FZ8 is a delivery order under SPE2DR25D3017, an indefinite delivery contract.
Was contract SPE2DR26F3FZ8 competed?
The extent of competition for SPE2DR26F3FZ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award